Objectives Recent evidence indicates that high-density lipoprotein (HDL) exerts vasculoprotective activities by promoting activating transcription factor 3 (ATF3), leading to downregulation of toll-like receptor (TLR)-induced inflammatory responses. Systemic lupus erythematosus (SLE) is associated with increased cardiovascular disease risk not explained by the Framingham risk score. Recent studies have indicated oxidised HDL as a possible contributor. We investigated the potential mechanisms by which lupus HDL may lose its anti-inflammatory effects and promote immune dysregulation. Methods Control macrophages were challenged with control and SLE HDL in vitro and examined for inflammatory markers by real-time qRT-PCR, confocal microscopy, ELISA and flow cytometry. Lupus-prone mice were treated with an HDL mimetic (ETC-642) in vivo and inflammatory cytokine levels measured by real-time qRT-PCR and ELISA. Results Compared with control HDL, SLE HDL activates NFκB, promotes inflammatory cytokine production and fails to block TLR-induced inflammation in control macrophages. This failure of lupus HDL to block inflammatory responses is due to an impaired ability to promote ATF3 synthesis and nuclear translocation. This inflammation is dependent on lectin-like oxidised lowdensity lipoprotein receptor 1 (LOX1R) binding and rhoassociated, coiled-coil containing protein kinase 1 and 2 (ROCK1/2) kinase activity. HDL mimetic-treated lupus mice showed significant ATF3 induction and proinflammatory cytokine abrogation. Conclusions Lupus HDL promotes proinflammatory responses through NFκB activation and decreased ATF3 synthesis and activity in an LOX1R-dependent and ROCK1/2-dependent manner. HDL mimetics should be explored as potential therapies for inflammation and SLE cardiovascular risk.
INTRODUCTION
Systemic lupus erythematosus (SLE) is an autoimmune syndrome of unclear aetiology characterised by profound dysregulation of innate and adaptive immune responses. Inflammatory cytokines, particularly type I interferons (IFNs), interleukin (IL) 6 and tumour necrosis factor (TNF), may lead to altered cellular activation in SLE. 1 Atherosclerotic cardiovascular disease (CVD) risk is significantly enhanced in SLE, independent of the Framingham risk score. 2 3 Oxidised, dysfunctional high-density lipoprotein (HDL) has been linked to both 'typical' and SLE-related CVD. When HDL becomes oxidised, it loses its cardioprotective effects and displays impaired cholesterol efflux capacity and decreased ability to block low-density lipoprotein (LDL) oxidation. [4] [5] [6] [7] [8] [9] [10] We recently demonstrated that neutrophil extracellular traps in lupus promote proatherogenic modifications (3-nitrotyrosine and 3-chlorotyrosine oxidation) in HDL and that oxidised lupus HDL displays impaired cholesterol efflux capacity. 7 What remains unclear is whether this modified SLE HDL promotes aberrant myeloid cell responses, leading to atherogenesis and systemic inflammation.
Monocytes and macrophages (Mϕ) within the vascular subendothelial space are key players in atherogenesis. 11 These cells express scavenger receptors (SR), including lectin-like oxidised low-density lipoprotein receptor 1 (LOX1R), CD36 and SR-AI/II and SR-BI, which can internalise lipoproteins. This interaction can either promote repair or inflammation and plaque formation, depending on cardiovascular health status. 11 As such, lipoprotein-mediated pathways that modify inflammatory responses in Mϕ can be crucial to mitigating CVD risk.
De Nardo et al recently demonstrated that unmodified, healthy HDL blocks toll-like receptor (TLR)-induced proinflammatory cytokine production through upregulation of activating transcription factor 3 (ATF3). 12 Upon activation, ATF3 translocates to the nucleus and recruits histone deacetylase-1 to the promoter regions of IL-6, TNF and IL-12B to repress their expression. 13 ATF3 may be particularly important for vascular health as, in vivo, HDL-induced arterial re-endothelialisation requires ATF3. 12 We therefore investigated if lupus oxidised HDL exerts similar anti-inflammatory pathways and affects ATF3 synthesis and function. 
METHODS
See online supplementary material for details.
Subject recruitment
SLE subjects (diagnosed per American College of Rheumatology criteria) and healthy control (Ctrl, see online supplementary  table S1 for demographics) sample collection was approved by University of Michigan and National Institutes of Health IRBs. Disease activity was quantified by SLEDAI-2K. 14 15 Pregnant or lactating women and individuals with recent or current infections or liver dysfunction were excluded.
HDL and ETC-642 preparation
Plasma HDL was purified (N=8 Ctrl, N=10 SLE) by sequential buoyant-density ultracentrifugation. 16 ETC-642 preparation is detailed online. 17 
Macrophage differentiation and culture
Adherent human PBMCs were cultured in X-Vivo-15 media (Lonza, Basel, Switzerland) with 10% fetal bovine serum (FBS) for 1 week. Cells were cultured in Dulbecco's Modified Eagle Medium (Life Technologies, Grand Island, New York, USA) with 2% lipoprotein deficient serum (EMD Millipore, Billerica, Massachusetts, USA), to minimise the effects of LDL in FBS. All HDL or ETC-642 in vitro treatments were at a concentration of 50 mg/mL. Individual Ctrl or SLE donor HDLs were used, not pooled samples. For receptor blocking experiments, Ctrl macrophages (CMϕ) were cultured with azide-free isotype control (1 mg/mL, Biolegend, San Diego, California, USA and SouthernBiotech, Birmingham, Alabama, USA), anti-LOX1R blocking antibody (5 mg/mL, R&D Systems, Minneapolis, Minnesota, USA) or anti-SR-AI/II blocking antibody (1 mg/mL, R&D Systems) for 30 min, before adding HDL. To block rho-associated, coiled-coil containing protein kinase 1 and 2 (ROCK1/2) activity, CMϕ were incubated with Y27632 (0.6 mM, Tocris, Bristol, UK) for 1 hour (for immunoblot, confocal microscopy, real-time qRT-PCR) or 2 hours (for ELISA) before HDL treatment.
Real-time qRT-PCR
To test the ability of HDL or ETC-642 to block TLR-induced inflammation, CMϕ were treated with media, Ctrl or SLE HDL for 4 hours prior to challenge with lipopolysaccharide (LPS, 100 ng/mL, Sigma-Aldrich, St. Louis, Missouri, USA), Pam3CSK4 (300 ng/mL, InvivoGen, San Diego, California, USA) or R848 (1 mg/mL, InvivoGen) for 4 hours. Real-time qRT-PCR was performed (BioRad, Hercules, California, USA) using the primer sequences listed in online supplementary table S2.
ELISA
For LOX1R or SR-AI/II blockade experiments, CMϕ were treated with isotype control or blocking antibodies (see above) for 30 min before addition of Ctrl or SLE HDL overnight (LOX1R blockade) or for 4 hours before addition of Pam3CSK4 (300 ng/mL, InvivoGen) overnight (SR-AI/II blockade). Antihuman cytokine ELISAs (ALPCO, Salem, New Hampshire, USA) were performed on supernatants. Antimouse IL-6 ELISA (eBioscience, San Diego, California, USA) was performed on mouse serum.
Confocal immunofluorescence microscopy
In the nuclear localisation experiments, CMϕ were treated with isotype control/blocking antibody (see above), then HDL for 30 min (ATF3) or 2 hours (NFκB p65) before fixation. Cells were blocked, stained with Hoechst 33342 (1:1000, Life Technologies), anti-p65 (Abcam, Cambridge, Massachusetts, USA), anti-LOX1R (Santa Cruz Biotechnology, Dallas, Texas, USA) or anti-ATF3 (Abcam) and fixed before imaging.
Immunoblot
Total lysate, nuclear fractions or immunoprecipitates were run on 4%-12% Bis-Tris gels (Life Technologies), blocked, stained and imaged on an Odyssey CLx (Li-cor, Lincoln, Nebraska, USA).
Flow cytometry
Cells were blocked, stained with anti-CD14 (Biolegend), anti-LOX1R (Biolegend), anti-ATF3 (Bioss, Woburn, Massachusetts, USA), anti-IL-6 and anti-TNF (eBioscience) and fixed before analysis.
In vivo administration of ETC-642
Lupus-prone NZM2328 (NZM) mice breeding pairs were obtained from Dr Chaim Jacob (University of Southern California).
7 NZM mice were treated (3 times/week via tail vein injection) with ETC-642 (15 mg/kg, N=8) or equal volume phosphate-buffered saline (PBS, N=8) starting at 10 weeks of age until they reached 23 weeks of age. Balb/c mice were purchased from Jackson Laboratory (Bar Harbor, Maine, USA).
Statistical analysis
Data are reported as mean±SEM. Statistical analysis was performed using Student's t-test or two-way analysis of variance. A p value <0.05 (GraphPad Prism, La Jolla, California, USA) was considered significant.
RESULTS

SLE HDL induces inflammatory responses and fails to abrogate TLR-induced inflammatory cytokine synthesis
Compared with Ctrl HDL treatment, lupus HDL induced significant increases in IL-6 and TNF mRNA (figure 1A) and protein (figure 1B, C; IL-6 and TNF) in Ctrl Mϕ (CMϕ). Confirming recent reports, preincubation of CMϕ with Ctrl HDL prior to TLR-4, TLR-1/2 or TLR-7/8 stimulation decreased the synthesis of IL-6 (figure 1D), TNF (figure 1E), IL-1β ( figure 1F ) and IL-12B mRNA (figure 1G). 4 12 In contrast, SLE HDL was impaired in its capacity to block TLR-induced inflammation (figure 1D-G), independent of TLR internalisation (see online supplementary figure S1A). Overall, these results indicate that SLE HDL promotes inflammatory responses in Mϕ and has an impaired ability to block TLR-induced inflammatory signals.
Lupus HDL fails to promote ATF3 synthesis
As lupus HDL promoted IL-6 and TNF production, we examined possible inflammatory signalling mechanisms. SLE HDL, but not Ctrl, promoted activation of the transcription factor NFκB in CMϕ, as quantified by p65 nuclear translocation (figure 2A). ATF3 is an anti-inflammatory transcriptional repressor of IL-6, TNF and IL-12B synthesis that is induced by Ctrl HDL. 12 13 Two hours after exposing CMϕ to HDL, SLE HDL showed decreased capacity to induce ATF3 mRNA compared with Ctrl HDL (figure 2B). By 6 hours, lupus HDL-induced significantly lower ATF3 mRNA than either Ctrl HDL or no HDL. This was confirmed at the protein level as Ctrl monocytes (figure 2C and see online supplementary figure S1B, C) or CMϕ (figure 2D) exposed to lupus HDL display significantly lower ATF3 compared with Ctrl HDL. Additionally, SLE macrophages (SMϕ) expressed lower levels of ATF3 than CMϕ by flow cytometry (figure 2E) and microscopy ( figure 2F ). These results suggest that, compared with Ctrl HDL, lupus HDL promotes NFκB activation and has decreased capacity to induce the expression of the inflammatory repressor ATF3.
Lupus HDL binds to LOX1R, prevents ATF3 nuclear translocation and promotes inflammatory responses in macrophages
Previous work demonstrated that HDL purified from coronary artery disease patients or oxidised by myeloperoxidase acquires the ability to bind LOX1R and initiate inflammation. 18 19 As lupus HDL contains enhanced levels of myeloperoxidasecatalysed 3-chlorotyrosine, we investigated if the inflammatory responses induced by lupus HDL require LOX1R binding. 7 We first verified LOX1R expression in Ctrl and SLE monocytes and Mϕ. While LOX1R was present in both Ctrl and SLE cells, a higher percentage of SLE monocytes were LOX1R + compared with Ctrl (see online supplementary figure S2A), although LOX1R mean fluorescent intensity did not differ between Ctrl and SLE monocytes (see online supplementary figure S2B). In contrast, SMϕ displayed higher LOX1R expression at the protein (see online supplementary figure S2C, D) and mRNA level than CMϕ (see online supplementary figure S2E). LOX1R levels (quantified by microscopy, flow cytometry and real-time .05, **p<0.01, ***p<0.0005, ****p<0.0001, ns, non-significant; fold change to media is relative to no HDL, no TLR agonist treatment.
qRT-PCR) did not correlate with SLEDAI. Furthermore, SLE HDL-induced significantly higher LOX1R levels than Ctrl HDL (see online supplementary figure S2F) in CMϕ.
We then examined the effects of SLE HDL on ATF3 activity. Since ATF3 blocks inflammation via epigenetic promoter modifications, its activity was assessed by its ability to translocate to the nucleus. Compared with Ctrl HDL, SLE HDL-treated CMϕ displayed significantly less nuclear ATF3 ( figure 3A) . To assess if this impairment was dependent on LOX1R binding, we incubated CMϕ with blocking anti-LOX1R or isotype control antibodies prior to addition of SLE or Ctrl HDL. By preventing the binding of SLE HDL to LOX1R, ATF3 nuclear translocation was restored ( figure 3A) while blockade prior to Ctrl HDL addition demonstrated no changes. This was confirmed by , following overnight incubation with Ctrl or SLE HDL (N=4). ATF3 levels in Ctrl and SLE macrophages (Mac) by (E) flow cytometry (N=3) or (F) confocal microscopy (Ctrl N=15, SLE N=12). Bar graphs are mean±SEM, *p<0.05, **p<0.01, ***p<0.0005, ****p<0.0001, ns, non-significant, A.U., arbitrary units.
immunoblot (see online supplementary figure S3A). These results suggest that SLE HDL binds to LOX1R and initiates a pathway that suppresses ATF3s anti-inflammatory activity. This was further examined by incubating CMϕ with anti-LOX1R blocking or isotype control antibodies, followed by SLE or Ctrl HDL overnight and quantifying IL-6 and TNF release by ELISA. LOX1R blockade significantly decreased SLE HDL-induced IL-6 (figure 3B) and TNF (figure 3C) release. Blocking LOX1R prior to addition of SLE HDL also significantly decreased NFκB activation by immunofluorescence (see online supplementary figure S3B) and immunoblot (see online supplementary figure S3C ). These results indicate that lupus HDL engagement with LOX1R blocks the activity of ATF3 and enhances NFκB activation, thereby promoting inflammatory cytokine synthesis in Mϕ.
SLE HDL impairs ATF3 activity in a ROCK1/2-dependent manner
Stimulation of LOX1R has been linked to activation of ROCK1/ 2, which then activates NFκB. 20 Given that ROCK1/2 are serine/threonine kinases and that ATF3 contains a threonine (Thr-162) phosphorylation site, we examined the role of ROCK1/2 on SLE HDL-induced inflammation and ATF3 activity. 21 CMϕ were incubated with or without Y27632, at a concentration that specifically blocks ROCK1/2 activity, prior to adding Ctrl or SLE HDL. 22 Immunoprecipitated ATF3 was then measured for phosphorylation. As Thr-162 on ATF3 is adjacent to a proline residue, we used a primary antibody that recognises only phosphorylated serine or threonine residues adjacent to a proline residue (no phos-ATF3 antibodies are commercially available). SLE HDL enhanced ATF3 phosphorylation, but not when preincubated with Y27632 (see online supplementary figure S4A ). This indicates that SLE HDL-activated ROCK1/2 targets ATF3 for phosphorylation.
We next examined the effect of ROCK1/2 on SLE HDL-induced inflammation and altered ATF3 localisation. CMϕ preincubated with Y27632 before SLE HDL treatment showed restoration of ATF3 nuclear translocation ( figure 4A ). In contrast, Y27632 did not modify Ctrl HDL-induced ATF3 nuclear localisation. Y27632 by itself increased ATF3 nuclear translocation, suggesting a putative effect from FBS lipoproteins. Finally, preincubation with Y27632 also impaired SLE HDL-induced Figure 3 Lupus high-density lipoprotein (HDL) binds LOX1R, blocks activating transcription factor 3 (ATF3) nuclear translocation and promotes inflammatory cytokine synthesis. (A) Preincubation with blocking anti-LOX1R antibody (anti-LOX1R) increases ATF3 nuclear translocation in CMϕ (N=12) exposed to systemic lupus erythematosus (SLE) HDL (N=7) for 30 min compared with isotype control (Iso). Images are representative of conditions performed in triplicate. Bar graph represents per cent of ATF3 that colocalises with DNA by weighted colocalisation coefficient. Anti-LOX1R modifies (B) Interleukin (IL) 6 and (C) tumour necrosis factor (TNF) secretion by CMϕ (N=12) exposed overnight to SLE (N=10), but not Ctrl HDL (N=6). Bar graphs are mean±SEM, **p<0.01, ***p<0.0005, ****p<0.0001. figure 4B ) and TNF protein ( figure 4C ) and mRNA (see online supplementary figure S4B,C) synthesis. These results suggest that oxidised SLE HDL binds LOX1R, activates ROCK1/2, which phosphorylates ATF3 and blocks its nuclear translocation, resulting in increased inflammation ( figure 4D ). As LOX1R expression is enhanced in SMϕ, these effects may be even more pronounced in lupus patients.
IL-6 (
SR-AI/II affects Ctrl HDL-induced anti-inflammatory activity and ATF3 mobility
The signalling cascade leading to Ctrl HDL-induced ATF3 activity remains unclear. SRs possibly contribute to this pathway as they are abundant on Mϕ, have been linked to CVD, and interact with lipoproteins. 10 11 We quantified mRNA levels of various SRs in CMϕ, compared with Ctrl monocytes, and found that SR-AI and SR-AII were the most significantly upregulated during differentiation (see online supplementary figure S5A,B) . We then tested whether Ctrl HDL interacts with SR-AI/II to modify ATF3 nuclear translocation. CMϕ preincubated with anti-SR-AI/II blocking antibody prior to addition of Ctrl HDL showed significantly lower nuclear ATF3 than isotype control or antibodies blocking other SRs (anti-CD36 or anti-SR-BI). Indeed, anti-SR-AI/II blockade prior to addition of Ctrl or SLE HDL promoted ATF3 aggregates in the cytoplasm (figure 5A).
As Ctrl HDL-induced ATF3 blocks TLR-induced inflammatory cytokine production, we assessed whether blockade of SR-AI/II suppressed this effect. CMϕ treated first with anti-SR-AI/II blocking antibody, then Ctrl HDL, and finally TLR-2 agonist Pam3CSK4 showed significantly increased IL-6 (figure 5B) and TNF (figure 5C) protein and mRNA (see online supplementary figure S5C, D) levels compared with control conditions (see online supplementary figure S5E, F) . This suggests that, in contrast to the observed interaction of SLE HDL with LOX1R, Ctrl HDL preferentially binds SR-AI/II to promote ATF3s anti-inflammatory activity.
The HDL mimetic ETC-642 abrogates the inflammatory effects of lupus HDL ETC-642 is an HDL mimetic compound composed of 22 amino acids (22A) derived from apolipoprotein A-I (ApoA-I, the most abundant protein in HDL) and the phospholipids 1,2-dipalmitoyl-sn-glycero-3-phosphocholine and sphingomyelin. ETC-642 improves cardiovascular parameters in animal models and mobilises cholesterol in plasma compartments in dyslipidemic patients. 17 23 As this compound mimics some of the anti-inflammatory effects of healthy HDL, we assessed its role in downregulating the deleterious effects of lupus HDL.
ETC-642 blocked TLR-induced IL-6 (figure 6A) and TNF (figure 6B) mRNA production in CMϕ (see online supplementary figure S6A and B for IL1-β and IL-12B), while its individual protein or lipid components did not (see online supplementary figure S6C,D) . Similarly, ATF3 nuclear translocation was induced by ETC-642 (figure 6C), but not its individual components (see online supplementary figure S6E). To address if ETC-642 could reverse the proinflammatory effects of lupus HDL, CMϕ were exposed to various ratios (based on protein Similar to human SLE, we previously showed that lupus-prone NZM mice display CVD-like endothelial dysfunction and enhanced levels of oxidised HDL. 24 We therefore . Bar graphs are mean±SEM,* p<0.05, **p<0.009, ***p<0.0008, ****p<0.0001, ns, non-significant, fold change to media is relative to no HDL treatment.
assessed if in vivo systemic administration of ETC-642 could decrease inflammatory cytokine synthesis in female NZM mice (see online supplementary figure S7A for pharmacokinetics).
Splenocytes from ETC-642-treated NZM mice displayed significant increases in Atf3, significant decreases in Il6, Tnf, Il1β, Il12b and IFN-stimulated genes when normalised to Balb/c splenocytes and compared with PBS-treated NZM mice (see online supplementary figure S7B). Indeed, when normalised to PBS-treated NZM mice and compared with non-autoimmune Balb/c mice (see online supplementary figure S7C), the splenocytes from ETC-treated lupus mice were not statistically different in Il6, Tnf and Il12b mRNA levels than healthy Balb/c mice, indicating that ETC-642 may be able to dampen the increased levels of these cytokines in lupus mice down to a level that is statistically indiscernible from a non-autoimmune mouse strain. ETC-treated NZM mice also showed significantly lower serum IL-6 levels (see online supplementary figure S6D ). ETC-642 did not modify autoantibodies or proteinuria (data not shown).
Overall, these results indicate that in vivo administration of the HDL mimetic ETC-642 can dampen cytokine synthesis in murine lupus.
DISCUSSION
Healthy (minimally oxidised) HDL shows an inverse correlation with CVD risk and promotes anti-inflammatory effects, including dampening of TLR-mediated responses in Mϕ. 5-8 10 25 It has been unclear if oxidative modifications of HDL modify the capacity of this lipoprotein to modulate TLR-induced responses or affect ATF3 activity. We tested this hypothesis in SLE subjects because they exhibit enhanced inflammatory cytokine synthesis, aberrant innate immune responses, enhanced HDL oxidation and increased CVD risk. 3 24 26 As Mϕ are crucial players in inflammation, understanding how oxidised HDL modulates Mϕ function is highly relevant in CVD and autoimmune disorders. 4 11 In contrast to the anti-inflammatory effects of Ctrl HDL on Mϕ, exposure to SLE HDL enhanced inflammatory cytokine production (even in the absence of TLR agonists) and failed to block TLR-induced cytokine production. The inflammatory effects promoted by lupus HDL required its binding to LOX1R, leading to enhanced ROCK1/2 activity and a failure to induce ATF3 synthesis and activity. In contrast, the anti-inflammatory effects of Ctrl HDL via ATF3 involved SR-AI/II binding. Importantly, an ApoA-I mimetic counteracted the deleterious effects of lupus HDL in vitro and also decreased levels of proinflammatory cytokines in murine SLE in vivo. While the mimetic did not affect autoantibody or proteinuria levels, future studies should explore if a beneficial effect may be observed using different doses of ETC-642, other lupus models or earlier assessments of disease activity. As this compound is devoid of tyrosine residues, it is not susceptible to CVD-associated regiospecific ApoA-I modifications. ETC-642 may therefore have therapeutic potential by counteracting proatherogenic and proinflammatory effects of lupus HDL and by engaging SRs associated with protective responses in macrophages. While to our knowledge clinical development of this compound has ceased, similar therapies could have potential benefit.
One conceivable explanation for how the SLE HDL:LOX1R interaction blocks ATF3 activity is by promoting degradation of ATF3 protein and/or mRNA. However, as differences in ATF3 nuclear translocation were detected as early as 30 min post-HDL treatment, this hypothesis is less likely. Instead, our results indicate that site-specific phosphorylation of ATF3 by ROCK1/2 promotes cytoplasmic ATF3 sequestration, thereby decreasing its anti-inflammatory effect. Future studies should address whether HDL from SLE and other chronic, inflammatory disorders (eg, rheumatoid arthritis) have different affinities for LOX1R, SR-AI/II, CD36 or other SRs. 16 The oxidation pattern alone may not fully explain lupus HDLs inflammatory activity. Circulating HDL can bind and trap neighbouring molecules that, in turn, could affect the lipoprotein's immunogenicity. Changes in phospholipid composition can affect the anti-inflammatory capacity of HDL. 27 Future analysis should explore differences in HDL lipid and protein cargo among different inflammatory conditions.
In conclusion, modified lupus HDL binds to LOX1R in Mϕ, leading to induction of NFκB activity and failure to induce ATF3 synthesis and activation through a ROCK1/2-dependent pathway, thereby promoting proinflammatory responses. As HDL mimetics modify proinflammatory effects of lupus HDL in vivo and in vitro, these therapies could potentially have cardioprotective and immunomodulatory roles in lupus and other autoimmune diseases associated to enhanced CVD risk.
